Literature DB >> 28257987

Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination.

Mona O Mohsen1, Ariane C Gomes2, Gustavo Cabral-Miranda2, Caroline C Krueger3, Fabiana Ms Leoratti3, Jens V Stein4, Martin F Bachmann5.   

Abstract

DNA rich in unmethylated CG motifs (CpGs) engage Toll-Like Receptor 9 (TLR-9) in endosomes and are well described stimulators of the innate and adaptive immune system. CpGs therefore can efficiently improve vaccines' immunogenicity. Packaging CpGs into nanoparticles, in particular into virus-like particles (VLPs), improves the pharmacological characteristics of CpGs as the protein shell protects them from DNAse activity and delivers the oligomers to the endosomal compartments of professional antigen presenting cells (APCs). The current consensus in packaging and delivering CpGs in VLP-based vaccines is that both adjuvants and antigens should be kept in close proximity (i.e. physically linked) to ensure delivery of antigens and adjuvants to the same APCs. In the current study, we harness the draining properties of the lymphatic system and show that also non-linked VLPs are efficiently co-delivered to the same APCs in lymph nodes. Specifically, we have shown that CpGs can be packaged in one VLP and mixed with another VLP displaying the antigen prior to administration in vivo. Both VLPs efficiently reached the same draining lymph node where they were taken up and processed by the same APCs, namely dendritic cells and macrophages. This resulted in induction of specific CTLs producing cytokines and killing target cells in vivo at levels seen when using VLPs containing both CpGs and chemically conjugated antigen. Thus, delivery of antigens and adjuvants in separate nanoparticles eliminates the need of physical conjugation and thus can be beneficial when designing precision medicine VLP-based vaccines or help to re-formulate existing VLP vaccines not naturally carrying immunostimulatory sequences.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Conventional dendritic cells (cDCs); Cytotoxic T-Lymphocytes (CTLs); Oligonucleotides rich in non-methylated CG motifs (CpGs); Plasmacytoid dendritic cells (pDCs); Toll-Like Receptor-9 (TLR-9); Virus-like particles (VLPs)

Mesh:

Substances:

Year:  2017        PMID: 28257987     DOI: 10.1016/j.jconrel.2017.02.031

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  27 in total

1.  Vaccine Adjuvant Incorporation Strategy Dictates Peptide Amphiphile Micelle Immunostimulatory Capacity.

Authors:  Rui Zhang; Jake S Kramer; Josiah D Smith; Brittany N Allen; Caitlin N Leeper; Xiaolei Li; Logan D Morton; Fabio Gallazzi; Bret D Ulery
Journal:  AAPS J       Date:  2018-06-01       Impact factor: 4.009

Review 2.  Biomaterials for vaccine-based cancer immunotherapy.

Authors:  Rui Zhang; Margaret M Billingsley; Michael J Mitchell
Journal:  J Control Release       Date:  2018-10-09       Impact factor: 9.776

Review 3.  Mechanisms of cellular and humoral immunity through the lens of VLP-based vaccines.

Authors:  Hunter McFall-Boegeman; Xuefei Huang
Journal:  Expert Rev Vaccines       Date:  2022-01-24       Impact factor: 5.217

Review 4.  Nanoparticles for generating antigen-specific T cells for immunotherapy.

Authors:  Savannah E Est-Witte; Natalie K Livingston; Mary O Omotoso; Jordan J Green; Jonathan P Schneck
Journal:  Semin Immunol       Date:  2021-12-23       Impact factor: 11.130

Review 5.  Improving Vaccine and Immunotherapy Design Using Biomaterials.

Authors:  Michelle L Bookstaver; Shannon J Tsai; Jonathan S Bromberg; Christopher M Jewell
Journal:  Trends Immunol       Date:  2017-12-14       Impact factor: 16.687

Review 6.  Current Research of Trichinellosis in China.

Authors:  Xue Bai; Xiaoxiang Hu; Xiaolei Liu; Bin Tang; Mingyuan Liu
Journal:  Front Microbiol       Date:  2017-08-02       Impact factor: 5.640

7.  Overcoming immunogenicity issues of HIV p24 antigen by the use of innovative nanostructured lipid carriers as delivery systems: evidences in mice and non-human primates.

Authors:  Emilie Bayon; Jessica Morlieras; Nathalie Dereuddre-Bosquet; Alexis Gonon; Leslie Gosse; Thomas Courant; Roger Le Grand; Patrice N Marche; Fabrice P Navarro
Journal:  NPJ Vaccines       Date:  2018-10-01       Impact factor: 7.344

8.  RNA and Toll-Like Receptor 7 License the Generation of Superior Secondary Plasma Cells at Multiple Levels in a B Cell Intrinsic Fashion.

Authors:  Caroline C Krueger; Franziska Thoms; Elsbeth Keller; Fabiana M S Leoratti; Monique Vogel; Martin F Bachmann
Journal:  Front Immunol       Date:  2019-04-05       Impact factor: 7.561

9.  Head-to-Head Comparison of Modular Vaccines Developed Using Different Capsid Virus-Like Particle Backbones and Antigen Conjugation Systems.

Authors:  Laurits Fredsgaard; Louise Goksøyr; Susan Thrane; Kara-Lee Aves; Thor G Theander; Adam F Sander
Journal:  Vaccines (Basel)       Date:  2021-05-21

Review 10.  Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune System.

Authors:  Mona O Mohsen; Ariane C Gomes; Monique Vogel; Martin F Bachmann
Journal:  Vaccines (Basel)       Date:  2018-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.